Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
NCT00612755
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
43
Enrollment
OTHER
Sponsor class
Conditions
HIV Infections
Hepatitis C
Interventions
DRUG:
Peginterferon alfa-2a + ribavirin
Sponsor
Hospital Clinico Universitario San Cecilio